🧫
experiment

APOEε4 carriers showed more rapid biomarker changes (decreasing Aβ42:Aβ40, increasing p-tau181, NfL, and GFAP) from midlife to late life compared to non-carriers.

🧫 Experiment Protocol ClinicalAlzheimer's diseaseAPOEhumanextracted
APOE genotyping performed; longitudinal biomarker changes compared between ε4 carriers and non-carriers
PRIMARY OUTCOME
APOEε4 carriers showed more rapid biomarker changes (decreasing Aβ42:Aβ40, increasing p-tau181, NfL, and GFAP) from midlife to late life compared to non-carriers.
LINKED HYPOTHESES
Source: pmid_39068543
🧫 Experiment Extras
PATHWAY
lipid metabolism
MARKET PRICE
$0.50
STATUS
extracted
Related Target
APOEcomposite 0.621
Prediction Markets (1 direct, 0 via hypothesis — 1 total)
APOEε4 carriers showed more rapid biomarker changes (decreasing Aβ42:Aβ40, increasing p-taYES 71% · Liq $100 · active
View on SciDEX ↗